Physician

Pathology

Rebecca McClure works in the field of Pathology. Dr. Rebecca F. McClure is a published MD as well. She has 50 publications published. The latest was: High-throughput sequencing using the ion torrent personal genome machine for clinical evaluation of somatic hypermutation status in chronic lymphocytic leukemia.

Publications

---

• High-throughput sequencing using the ion torrent personal genome machine for clinical evaluation of somatic hypermutation status in chronic lymphocytic Leukemia.
• Clonal mast cell Disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis.
• Microgranular variant of Acute promyelocytic leukemia with normal conventional cytogenetics, negative PML/RARA FISH and positive PML/RARA transcripts by RT-PCR.
• PAX5-positive T-cell anaplastic large cell Lymphomas associated with extra copies of the PAX5 gene locus.
• Epstein-Barr virus-associated diffuse large B-cell Lymphoma arising on cardiac prostheses.
• WHO subvariants of indolent Mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults.
• Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other Myeloid malignancies.
• Chronic myeloid Leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.
• Systemic Mastocytosis in 342 consecutive adults: survival studies and prognostic factors.
• Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell Lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior.
• Tumor suppressor p16 methylation in multiple Myeloma: biological and clinical implications.
• MPL515 mutations in myeloproliferative and other Myeloid disorders: a study of 1182 patients.
• Lenalidomide therapy in myelofibrosis with Myeloid metaplasia.
• Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.
• The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants.
• Adult B-cell Lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.
• The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and Myelodysplastic syndromes.
• Histiocytes containing immunoglobulin crystals in the urine of a patient with IgA kappa plasmacytoma of the bladder.
• A new method to extract nuclei from paraffin-embedded tissue to study Lymphomas using interphase fluorescence in situ hybridization.
• Amiodarone-induced bone marrow granulomas: an unusual cause of reversible Pancytopenia.
• MPL W515 and JAK2 V617 mutation analysis in patients with refractory Anemia with ringed sideroblasts and an elevated platelet count.
• 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
• Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
• Agnogenic Myeloid metaplasia with pleural extramedullary leukemic transformation.
• JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
• Multiple Myeloma presenting initially as a solitary pleural effusion later complicated by malignant plasmacytic ascites.
• JAK2(V617F) and leukemic transformation in myelofibrosis with Myeloid metaplasia.
• Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/Myelodysplastic syndrome with an aggressive clinical course.
• JAK2 V617F is a rare finding in de novo Acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
• Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.
• Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myel...
• IDH1 and IDH2 mutation analysis in Chronic- and blast-phase myeloproliferative neoplasms.
• Discordant distribution of JAK2V617F mutation in siblings with familial Myeloproliferative disorders.
• A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with Myeloid metaplasia: analysis at two time points.
• Serous borderline tumor of the paratestis: a report of seven cases.
• IDH1 and IDH2 mutation studies in 1473 patients with Chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
• A phase-2 trial of low-dose pomalidomide in myelofibrosis.
• Use of multiple displacement amplification to amplify genomic DNA before sequencing of the alpha and beta haemoglobin genes.
• Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-Cell lineage malignancy identify a new breakpoint cluster region designated BVR2.
• Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in Chronic myeloproliferative disorders.
• Recurrent IDH mutations in high-risk myelodysplastic syndrome or Acute myeloid leukemia with isolated del(5q).
• Clonal relationship between precursor B-cell Acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases.
• Constitutive Fas ligand gene transcription in Sertoli Cells is regulated by Sp1.
• Elimination of senescent neutrophils by TNF-related apoptosis-inducing [corrected] ligand.
• Validation of immunoglobulin gene rearrangement detection by PCR using commercially available BIOMED-2 primers.
• Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
• The Alpha-1 Association Genetic Counseling Program: an innovative approach to service.
• Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
• Instructive case report. A 26-year-old Indian woman with seizures and multiple intracranial mass lesions.

Conditions Treated

---

• Acute Leukemia
• Anemia
• Chronic Myeloid Leukemia (CML)
• Hodgkin's Disease
• View All

Doctors Specialties

---

• Hematology
• Hematopathology
• Pathology

Accepted Insurances

---

Education

---

• Mayo School of Graduate Medical Education
• University of Toronto Faculty of Medicine

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1326269473
Last Name Of The Provider	MCCLURE
First Name Of The Provider	REBECCA
View All

Similar Doctors

---

	Dr. Roxana S. Dronca, MD This Doctor is OpenDoctor Recommended.
	Dr. Kevin C. Halling, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Paula J. Santrach, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Herschel A. Carpenter, MD This Doctor is OpenDoctor Recommended.
	Dr. Ryan E. Wilcox, MD
	Dr. Erin L. Schenk, MD This Doctor is OpenDoctor Recommended.
	Dr. Kebede Hussein, MD
	Dr. Justin D. Kreuter, MD This Doctor is OpenDoctor Recommended.
	Dr. Liping Liu, MD
	Dr. Brandon T. Larsen, MD
	Dr. Min Shi, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog